Patents by Inventor Pierre Hamel

Pierre Hamel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6743802
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: June 1, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • Patent number: 6677351
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Patent number: 6657983
    Abstract: A method of allocating bandwidth for transmitting upstream cells from a CPE unit to a BTS. The CPE determines arrival time information associated with each cell and sends arrival time information associated with at least one cell to the BTS. The BTS allocates future bandwidth to the CPE as a function of the arrival time information received from the CPE. For example, the BTS estimates the number of cell arrivals occurring in the current scheduling period based on past cell arrival times. The BTS then sends information to the CPE in which the allocated future bandwidth is specified. Finally, the CPE groups a number of cells into a burst packet occupying the allocated bandwidth and sends the burst packet to the BTS. Rather than respond in a delayed manner to a bandwidth deficiency or surplus at an individual CPE unit, the BTS produces an estimate of a CPE unit's bandwidth demands, resulting in more efficient bandwidth utilization and reduced cell loss ratio.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: December 2, 2003
    Assignee: Nortel Networks Limited
    Inventors: Mieczyslaw J. Surazski, James Aweya, Imed Frigui, Pierre A. Hamel, Delfin Y. Montuno, Tong Shan, Bernard Thiboutot, Genzao G. Zhang
  • Publication number: 20030179133
    Abstract: This invention relates to a system for orienting and guiding visually impaired pedestrians. The system combines a Global Positioning System (GPS) receiver to a dead reckoning unit that compensates for GPS imprecision and loss of signal. The system is highly portable: it is based on a handheld portable computing platform that communicates wirelessly with a self-powered strap containing the GPS receiver and the dead reckoning unit. The system also uses wireless protocols to receive additional orientation information from a remote location server or operator accessible through the internet.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 25, 2003
    Inventors: Gilles Pepin, Manon Gaudet, Pierre Hamel
  • Publication number: 20030114478
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: August 23, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • Publication number: 20030096829
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: May 24, 2002
    Publication date: May 22, 2003
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Patent number: 6399636
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Publication number: 20020013347
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pylidyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 16, 2001
    Publication date: January 31, 2002
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Patent number: 6200993
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). or a pharmaceutically acceptable salt or hydrate thereof. The invention also encompasses pharmaceutical compositions and methods for treatment.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: March 13, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Bernard Cote, Richard Friesen, Richard Frenette, Mario Girard, Yves Girard, Cedrickx Godbout, Daniel Guay, Pierre Hamel, Marc Blouin, Yves Ducharme, Sylvie Prescott
  • Patent number: 6180650
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). The invention also encompasses pharmaceutical compositions and methods for treatment.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: January 30, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Frenette, Richard Friesen, Mario Girard, Yves Girard, Cedrickx Godbout, Daaniel Guay, Pierre Hamel, Helene Perrier
  • Patent number: 6057319
    Abstract: The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: May 2, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cameron Black, Serge Leger, Petpiboon Prasit, Zhaoyin Wang, Pierre Hamel, Yongxin Han, Gregory Hughes
  • Patent number: 5907537
    Abstract: An OA&M system is provided for a network communication core having a switch, a controller, and a core configuration memory. All configuration information which is static (i.e., information which remains the same regardless of the configuration of the core) is placed off-core in a map file. Because of this, requests for information on the configuration of the core may often be satisfied without the need to query the core, thereby reducing core load. Further, this static information in the map file allows validation of requests for dynamic configuration information as well as requests for reconfiguration of the core. In other words, the static information assists in ensuring that requests are proper. The static information in the map file is presented as "list", "attribute", and "choice" features. This presentation facilitates the making of OA&M requests by a user. The features become arguments of functions in order to generate OA&M requests to the controller.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: May 25, 1999
    Assignee: Northern Telecom Limited
    Inventors: Mario R. J. Papineau, Christopher R. Solar, Pierre A. Hamel, Eric Fredine, Ian W. Olthof, Mathew N. Perkins
  • Patent number: 5710170
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme, Marc Blouin, Pierre Hamel, Mario Girard
  • Patent number: 5698584
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: December 16, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cameron Black, Serge Leger, Petpiboon Prasit, Zhaoyin Wang, Pierre Hamel, Yongxin Han, Gregory Hughes
  • Patent number: 5639780
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 17, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques-Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • Patent number: 5604253
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Cameron Black, Daniel Guay, Jacques Y. Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • Patent number: 5576338
    Abstract: Compounds having the Formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: November 19, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Friesen, Yves Ducharme, Daniel Dube', Carole Lepine, Daniel Delorme, Pierre Hamel
  • Patent number: 5428060
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: June 27, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, John W. Gillard, Rejean Fortin, Daniel Dube, Yves Girard, Pierre Hamel, Daniel Delorme
  • Patent number: 5426109
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: June 20, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Girard, Pierre Hamel